Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$86.22
$0.15(0.17%)
At close: 4:00 PM EDT
$86.22
$0.15(0.17%)
Day’s Range― - ―
52-Week Range$19.02 - $91.36
Previous CloseN/A
Volume722.63K
Average Volume (3M)2.05M
Market Cap
$7.48B
Enterprise Value$3.78K
Total Cash (Recent Filing)$222.79M
Total Debt (Recent Filing)$184.82M
Price to Earnings (P/E)351.8
Beta1.55
Next Earnings
Aug 12, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding88,928,100
10 Day Avg. Volume1,538,855
30 Day Avg. Volume2,045,880
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$87.29Price Target Upside1.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.32
Revenue Forecast (FY)$725.12M
Bulls Say, Bears Say
Bulls Say
Commercial Traction And Rapid UptakeSustained, scaled commercial traction indicates the company has moved from launch to recurring revenue generation. A >$0.5B run rate and accelerating quarterly sales create a durable revenue base that supports reinvestment in sales, manufacturing scale-up, and clinical programs while reducing execution risk versus early-stage launches.
Converted To Positive Operating And Free Cash FlowPositive operating and free cash flow materially improves financial flexibility and lowers financing dependency. Reliable cash generation funds manufacturing expansion and clinical trials internally, reduces dilution risk, and provides a buffer against execution setbacks, strengthening near-term balance sheet resilience.
Proprietary PRINT Technology And Funded PipelineOwning differentiated particle-engineering IP creates a structural competitive advantage in inhaled therapeutics, enabling product differentiation (dosing, stability, delivery). Combined with self-funding of clinical programs, the platform supports durable pipeline optionality and potential label expansions without immediate external capital.
Bears Say
Ongoing Patent Litigation RiskPending patent litigation threatens exclusivity and could materially impair revenue if adverse rulings limit market access or delay launches. Legal outcomes are binary and can take many quarters, creating sustained downside risk to revenue predictability, margins and R&D prioritization until resolved.
Dosing Convenience May Constrain AdoptionA four-times-daily regimen can reduce adherence and limit uptake in broader community settings versus more convenient competitors. Unless L606 or other formulations succeed, prescribing depth and patient persistence could plateau, slowing sustainable market penetration and making revenue growth more contingent on education efforts.
Material Debt Relative To EquitySizable debt constrains strategic flexibility and raises susceptibility to interest or refinancing risk if cash generation weakens. While leverage improved, remaining obligations could limit M&A, capex choices or require excess cash allocation to service debt, making long-term investment decisions more sensitive to operational volatility.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $19.02 and its highest was $91.36 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $7.48B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Aug 12, 2026 which is in 6 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on May 11, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is 0.76.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 88,928,100 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of $0.52 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 25.603%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.29 (1.24% Upside)
$87.29 (1.24% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 92%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 25.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $132.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
359.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
76.55%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: rapid revenue and profitability growth, expanding market share, growing prescription breadth and depth, and a well-funded clinical pipeline. Primary risks cited were legal uncertainty, the need for continued market education (especially in PH-ILD and community settings), dosing convenience considerations (addressable by L606), and timing of broader indication studies. Overall, positives substantially outweigh the challenges described.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$87.29
▲(1.24% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.42% Insiders
8.46% Mutual Funds
2.79% Other Institutional Investors
40.09% Public Companies and Individual Investors